Corbus Pharmaceuticals to Present at the 36th Annual Oppenheimer Healthcare Life Sciences Conference

About this update from Corbus Pharmaceuticals Holdings, Inc.

NORWOOD, Mass., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings Inc. (NASDAQ: CRBP), a clinical-stage company focused on oncology and obesity, today announced that Yuval Cohen, Ph.D., Chief Executive Officer of Corbus, will present a corporate overview and attend investor meetings at the 36 th Annual Oppenheimer Healthcare Life Sciences Conference, to be held virtually February 25-25, 2026. 36 th Annual Oppenheimer Healthcare Life Sciences Conference Format: Virtual presentation and one-on-one investor meetings Date: February 25, 2026 Presentation Time: 3:20pm Eastern Time Webcast Link: Click Here About Corbus Corbus Pharmaceuticals Holdings, Inc. is a clinical stage oncology and obesity company with a diversified portfolio and is committed to helping people defeat serious illness by bringing innovative scientific approaches to well understood biological pathways. Corbus’ pipeline includes CRB-701, a next generation antibody drug conjugate that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload; CRB-601, an anti-integrin monoclonal antibody which blocks the activation of TGFβ expressed on cancer cells; and CRB-913, a highly peripherally restricted CB1 inverse agonist for the treatment of obesity. Corbus is headquartered in Norwood, Massachusetts. For more information on Corbus, visit  corbuspharma.com . Connect with us on  X ,  LinkedIn  and  Facebook . INVESTOR CONTACTS: Sean Moran Chief Financial Officer Corbus Pharmaceuticals [email protected] Dan Ferry Managing Director LifeSci Advisors, LLC [email protected]

View stock analysis, news, and events for Corbus Pharmaceuticals Holdings, Inc.